NuCana plc American Depositary Share
Compare this stock
NCNA Stock Report Card
$
35%
Performance
Score:
10/100
NCNA returned -59.09% in the last 12 months. Based on SPY's performance of 11.53%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
94/100
4 analysts offer 12-month price targets for NCNA. Together, they have an average target of 0, the most optimistic target put NCNA at 0 within 12-months and the most pessimistic has NCNA at 0.
Sentiment
Score:
65/100
NCNA had a bullish sentiment score of 65.09% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 1.33 comments, and 2.58 likes per day.
Technicals
Score:
11/100
NCNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
Score:
10/100
NCNA has missed earnings 7 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, NCNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
54/100
NCNA has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.
NuCana plc American Depositary Share Summary
Nasdaq / NCNA
Healthcare
Biotechnology
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
NCNA scored poorly on our reportcard. Here are some similar companies and how they performed.